Short form of TET1 linked to myelodysplastic syndromes (MDS)
Official title: Role of the TET1 short isoform in MDS development and maintenance
Funded at Beckman Research Institute/city of Hope · NIH-11469145 · Data updated 2026-11-12
Looks at whether a shorter version of the TET1 protein disrupts blood stem cells and contributes to myelodysplastic syndromes in people with or at risk for MDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | January 20, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $371,790 |
| NIH project number | 7R01HL157539-05 |
| Project ID | NIH-11469145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with myelodysplastic syndromes or people with abnormal blood counts who are willing to provide bone marrow samples would be ideal candidates to inform this work.
✕Less likely to help
People seeking immediate treatment changes or those without blood or bone marrow disorders are unlikely to receive direct medical benefit from this mechanistic research.
What this research studies
Researchers will measure levels of the short TET1-S protein in bone marrow samples from people with MDS and from healthy donors to confirm its association with disease. They will test how TET1-S changes hematopoietic stem cell behavior using patient-derived cells and laboratory models. Molecular and genetic experiments will examine how TET1-S alters DNA methylation and gene activity to produce MDS-like changes. The team will use these results to look for biomarkers or molecular targets that could guide future diagnostics or treatments.
Why it matters
Potential benefit: Could reveal a new biomarker or therapeutic target that helps detect, prevent, or treat MDS in the future.
How similar studies have gone: Prior studies link TET family proteins to blood cancers and show TET1-S is upregulated in MDS, but the specific role of this short isoform remains largely unproven and is relatively novel.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Qian, Zhijian — Beckman Research Institute/city of Hope
- Study coordinator: Qian, Zhijian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.